Hirohiko Shibayama

12PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersNanomedicineMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 28, 2026
A Survey Study of Patient-Physician Communication and Treatment Decision-Making Preference at Treatment Initiation and After Disease Stabilization in Newly Diagnosed Multiple Myeloma.

|Mar 29, 2024
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).

Hirohiko Shibayama, Mitsuhiro Itagaki, Hiroshi Handa

|Mar 01, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.

Yasunori Kogure, Hiroshi Handa, Yuta Ito

|Dec 02, 2021
A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement.

Yukiko Doi, Takafumi Yokota, Hirohiko Shibayama

|Mar 25, 2021
High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.

Hideaki Saito, Hiroaki Miyoshi, Hirohiko Shibayama

|Mar 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Thierry Facon, Christopher P Venner, Nizar J Bahlis

Pageof 2

Frequent Collaborators

2 joint publications

Koji Izutsu

2 joint publications

Masaki Iino

1 joint publications

Noriko Fukuhara

1 joint publications

Tomoko Yanai